e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Regulation of airway hyperresponsiveness and bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
E. Kerwin, A. D‘Urzo, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Medford, Lakewood, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain)
Source:
Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Session:
Regulation of airway hyperresponsiveness and bronchodilators
Session type:
Thematic Poster Session
Number:
1235
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Kerwin, A. D‘Urzo, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Medford, Lakewood, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain). Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I. Eur Respir J 2010; 36: Suppl. 54, 1235
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Tiotropium bromide: Efficacy and safety in complex treatment of COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
Source: International Congress 2018 – COPD management
Year: 2018
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Pooled analysis of twice-daily aclidinium bromide in COPD patients: Dyspnea and health status in the ACCORD-COPD I and ATTAIN trials
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept